What's in West Japan Thoracic Oncology Group's pipeline?

West Japan Thoracic Oncology Group has 3 drugs in our index: 0 marketed, 0 filed, 3 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with West Japan Thoracic Oncology Group's portfolio?

Top competitors by shared drug class: Agendia, Asan Medical Center, Children's Cancer Group, China, China Breast Cancer Clinical Study Group, Fujian Medical University.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/west-japan-thoracic-oncology-group.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-18 · How we verify

West Japan Thoracic Oncology Group — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

West Japan Thoracic Oncology Group pipeline: 0 marketed, 0 filed, 3 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 3 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Paclitaxel+Carboplatin/concurrent radiation	Paclitaxel+Carboplatin/concurrent radiation	phase 3	Chemotherapy combination with radiation		Oncology
Cisplatin+Vindesine+MMC/ concurrent radiation	Cisplatin+Vindesine+MMC/ concurrent radiation	phase 3	Chemotherapy combination regimen		Oncology
Irinotecan+Carboplatin/concurrent radiation	Irinotecan+Carboplatin/concurrent radiation	phase 3	Chemotherapy combination with concurrent radiation	Topoisomerase I (irinotecan); DNA (carboplatin and radiation)	Oncology

Therapeutic area mix

Oncology · 3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Agendia · 1 shared drug class
Asan Medical Center · 1 shared drug class
Children's Cancer Group, China · 1 shared drug class
China Breast Cancer Clinical Study Group · 1 shared drug class
Fujian Medical University · 1 shared drug class
MIPO Clinic · 1 shared drug class
Nanjing Yoko Biomedical Co., Ltd. · 1 shared drug class
AGO Study Group · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for West Japan Thoracic Oncology Group:

Cite this brief

Drug Landscape (2026). West Japan Thoracic Oncology Group — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/west-japan-thoracic-oncology-group. Accessed 2026-05-18.